STOCK TITAN

Schrodinger Inc - SDGR STOCK NEWS

Welcome to our dedicated news page for Schrodinger (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Schrodinger's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Schrodinger's position in the market.

Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) presented the discovery of SGR-1505, its MALT1 inhibitor, at the ACS Spring 2024 Meeting. SGR-1505 is being evaluated in a Phase 1 study for B-cell malignancies. Schrödinger's computational platform expedited the discovery process, leading to the selection of SGR-1505 as the development candidate in just 10 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
Rhea-AI Summary
Schrödinger, Inc. (SDGR) granted stock options and RSUs to newly hired employees as part of its 2021 Inducement Equity Incentive Plan. The stock options have an exercise price of $26.04 per share and a ten-year term, while the RSUs vest over four years. These grants were made to attract talent and align employee interests with company growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
Rhea-AI Summary
Schrödinger, Inc. (SDGR) achieved a 44% increase in fourth-quarter software revenue, totaling $68.7 million, and reported 20% annual total revenue growth, reaching $216.7 million. The company expects 6% to 13% software revenue growth in 2024. Schrödinger's CEO, Ramy Farid, highlighted the progress made in 2023, focusing on platform advancements and pipeline expansion, including two clinical-stage programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.84%
Tags
earnings
Rhea-AI Summary
Schrödinger (SDGR) to participate in key healthcare and biopharma conferences in March 2024, offering investors insights into the company's innovative computational platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
conferences
-
Rhea-AI Summary
Schrödinger, Inc. (SDGR) granted non-statutory stock options and restricted stock units to newly hired employees as part of their employment compensation. The stock options have an exercise price of $26.58 per share and a ten-year term, while the RSUs vest over four years. These grants were made under the company's 2021 Inducement Equity Incentive Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.43%
Tags
none
-
Rhea-AI Summary
Schrödinger (SDGR) will release its Q4 and full-year 2023 financial results on February 28, 2024, after market close. A conference call and webcast will follow at 4:30 p.m. ET, accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
earnings
Rhea-AI Summary
Schrödinger, Inc. (SDGR) granted non-statutory stock options and restricted stock units to newly hired employees as a material inducement to their employment. The stock options have an exercise price of $27.41 per share, a ten-year term, and vest over four years, while the RSUs vest over four years as well. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan and were approved by the compensation committee of the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) announces an expanded, three-year software agreement with Eli Lilly and Company. The agreement provides Lilly with large-scale access to Schrödinger’s full suite of technologies to enable and accelerate all stages of drug discovery. Schrödinger also provided an update on its progress across the business and announced its development and operational goals for 2024, including advancing its proprietary pipeline and driving software adoption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options to purchase 1,800 shares of the company’s common stock and restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. The stock options have an exercise price of $31.37 per share, a ten-year term, and vest over four years. The RSUs also vest over four years, with 25 percent vesting after 12 months of continuous service and the balance vesting in successive installments. These grants were made as a material inducement to the employees’ acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
none
Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) presents data on SGR-1505's Phase 1 study, expansion of portfolio with EGFRC797S, PRMT5-MTA, and NLRP3 programs, and development efforts targeting synthetic lethality and DNA-damage repair mechanisms. The company also outlines anticipated milestones and provides a detailed review of its proprietary drug discovery and development programs during its Pipeline Day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.09%
Tags
none
Schrodinger Inc

Nasdaq:SDGR

SDGR Rankings

SDGR Stock Data

1.93B
61.36M
2.42%
92.48%
7.48%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About SDGR

schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. the predictive power of schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company nimbus therapeutics. through significant long-term investments in basic research, schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. hundreds of peer-reviewed scientific publications by schrödinger scientists are frequently among the most heavily cited in their fields. founded in 1990, schrödinger has operations in the us, europe, japan, and india, with business part